Notice Number: NOT-DA-08-024

RFP Available: N01DA-8-8876

Key Dates
Release Date: January 15, 2008
Proposal Due Date: March 10, 2008

Issued by
National Institute on Drug Abuse (NIDA)

The National Institute on Drug Abuse intends to solicit for evaluating the efficacy of potential drug abuse treatment medications in non-human primates. Specifically, Rhesus monkeys will be trained in either drug discrimination or self administration procedures using cocaine or possibly other drugs of abuse. Test compounds will be provided under blinded conditions with all information regarding dose, vehicle and pre-treatment time supplied by NIDA. The successful offeror will evaluate the test compound for its effects to either substitute or antagonize the discriminative stimulus effects of the training drug, or for its effects on the self-administration dose effect curve of the training compound using standard protocols to be agreed upon in advance. Standardized, detailed reports with graphs will be prepared and submitted promptly to the program for each compound tested. Approximately 5-12 compounds per year will be tested using drug discrimination procedures, and another 4-8 compounds will be tested using self-administration procedures. In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that the successful offeror possess a DEA Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances. All offerors must comply with NIH guidelines on the care and use of laboratory animals. We anticipate the award of one cost reimbursement contract for a period of five years. The contract will include additional quantity options. RFP No. N01DA-8-8876 will be available electronically on or about January 24, 2008. You can access the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov ) or through the NIDA website: (URL: http://www.nida.nih.gov/RFP/RFPList.html ). All information required for the submission of a proposal will be contained in or accessible through the RFP package. Response to the RFP will be due on or about March 10, 2008. NIDA will consider proposals submitted by any responsible offeror. This advertisement does not commit the Government to award a contract.

Inquiries

Kenneth E. Goodling, Contracting Officer
National Institute on Drug Abuse, NIH
NIDA R&D Contracts Management Branch
6101 Executive Blvd., Room 260, MSC 8402
Bethesda, Maryland 20892-8402
E-mail: kg25d@nih.gov
Telephone: (301) 443-6677
Fax: (301) 443-7595